Bayer Total Assets 2010-2024 | BAYRY

Bayer total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Bayer total assets for the quarter ending September 30, 2024 were $117.598B, a 7.84% decline year-over-year.
  • Bayer total assets for 2023 were $125.827B, a 4.37% decline from 2022.
  • Bayer total assets for 2022 were $131.57B, a 7.51% decline from 2021.
  • Bayer total assets for 2021 were $142.257B, a 6.4% increase from 2020.
Bayer Annual Total Assets
(Millions of US $)
2023 $125,827
2022 $131,570
2021 $142,257
2020 $133,702
2019 $141,409
2018 $149,143
2017 $84,871
2016 $91,005
2015 $82,077
2014 $93,362
2013 $68,164
2012 $66,023
2011 $73,491
2010 $68,395
2009 $71,183
Bayer Quarterly Total Assets
(Millions of US $)
2024-09-30 $117,598
2024-06-30 $129,076
2024-03-31 $130,155
2023-12-31 $125,827
2023-09-30 $127,606
2023-06-30 $132,666
2023-03-31 $134,231
2022-12-31 $131,570
2022-09-30 $131,953
2022-06-30 $137,063
2022-03-31 $141,153
2021-12-31 $142,257
2021-09-30 $137,435
2021-06-30 $137,873
2021-03-31 $143,198
2020-12-31 $133,702
2020-09-30 $139,719
2020-06-30 $136,170
2020-03-31 $138,423
2019-12-31 $141,409
2019-09-30 $145,409
2019-06-30 $144,305
2019-03-31 $147,885
2018-12-31 $149,143
2018-09-30 $150,516
2018-06-30 $162,826
2018-03-31 $92,674
2017-12-31 $84,871
2017-09-30 $89,950
2017-06-30 $90,896
2017-03-31 $81,664
2016-12-31 $91,005
2016-09-30 $85,412
2016-06-30 $85,255
2016-03-31 $84,537
2015-12-31 $82,077
2015-09-30 $82,855
2015-06-30 $83,651
2015-03-31 $86,504
2014-12-31 $93,362
2014-09-30 $80,427
2014-06-30 $75,365
2014-03-31 $77,374
2013-12-31 $68,164
2013-09-30 $68,744
2013-06-30 $69,429
2013-03-31 $69,836
2012-12-31 $66,023
2012-09-30 $66,134
2012-06-30 $67,260
2012-03-31 $71,208
2011-12-31 $73,491
2011-09-30 $73,515
2011-06-30 $73,463
2011-03-31 $70,846
2010-12-31 $68,395
2010-09-30 $67,328
2010-06-30 $69,771
2010-03-31 $74,094
2009-12-31 $71,183
2009-09-30 $73,923
2009-06-30 $70,410
2009-03-31 $72,059
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $19.295B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $728.847B 75.49
Novo Nordisk (NVO) Denmark $381.440B 27.51
Johnson & Johnson (JNJ) United States $347.829B 14.11
AbbVie (ABBV) United States $310.275B 16.33
Merck (MRK) United States $248.031B 16.48
AstraZeneca (AZN) United Kingdom $202.626B 17.24
Novartis AG (NVS) Switzerland $198.493B 13.19
Pfizer (PFE) United States $149.382B 10.22
Sanofi (SNY) $121.080B 10.97
Innoviva (INVA) United States $1.117B 9.29